Clinical Trials
5 trialsNCT05764941 2023-03-27
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Unknown
NCT04115410 2020-05-28
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Unknown
NCT04208854 2019-12-26
VINORELBINA
International Group of Endovascular Oncology
Unknown
NCT03925233 2019-04-24
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
Unknown
NCT01752517 2012-12-19
Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer
Peking Union Medical College Hospital
Unknown